New Maui Derm 2026 data: Patients with head & neck atopic dermatitis who had inadequate response to dupilumab showed significant improvements after switching to upadacitinib, including higher EASI75/90/100 rates. www.hcplive.com/view...
February 7, 2026 at 7:00 PM
New Maui Derm 2026 data: Patients with head & neck atopic dermatitis who had inadequate response to dupilumab showed significant improvements after switching to upadacitinib, including higher EASI75/90/100 rates. www.hcplive.com/view...
#MedCase - An 81-year-old receiving #upadacitinib for RA developed CMV #retinitis complicated by delayed retinal ischemia and vitreous hemorrhage.
Clinicians should be vigilant for atypical ocular complications from JAK inhibitors.
👉 buff.ly/lrgZrQr
#EyeSky #IDSky #arthritis
Clinicians should be vigilant for atypical ocular complications from JAK inhibitors.
👉 buff.ly/lrgZrQr
#EyeSky #IDSky #arthritis
From infection to infarction: cytomegalovirus retinitis complicated by retinal ischemia and vitreous hemorrhage in the setting of JAK inhibition - a case report
An 81-year-old receiving upadacitinib for rheumatoid arthritis developed CMV retinitis complicated by delayed retinal ischemia and vitreous hemorrhage. Clinicians should be vigilant for atypical…
buff.ly
February 6, 2026 at 11:54 AM
#MedCase - An 81-year-old receiving #upadacitinib for RA developed CMV #retinitis complicated by delayed retinal ischemia and vitreous hemorrhage.
Clinicians should be vigilant for atypical ocular complications from JAK inhibitors.
👉 buff.ly/lrgZrQr
#EyeSky #IDSky #arthritis
Clinicians should be vigilant for atypical ocular complications from JAK inhibitors.
👉 buff.ly/lrgZrQr
#EyeSky #IDSky #arthritis
🤖 Automated message
16 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-02-05.html
Changes: paclitaxel albumin, entrectinib, vandetanib, Bosutinib, vedolizumab, upadacitinib hemihydrate,...
16 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-02-05.html
Changes: paclitaxel albumin, entrectinib, vandetanib, Bosutinib, vedolizumab, upadacitinib hemihydrate,...
Updated Summary of Product Characteristics – Chemotherapy Updates
Providing automated updates about changes to chemotherapy commissioning, consent, and licenses.
updates.chemo.org.uk
February 5, 2026 at 3:23 PM
🤖 Automated message
16 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-02-05.html
Changes: paclitaxel albumin, entrectinib, vandetanib, Bosutinib, vedolizumab, upadacitinib hemihydrate,...
16 cancer treatment summary of product characteristics have been updated recently.
https://updates.chemo.org.uk/news/SPC_updates_2026-02-05.html
Changes: paclitaxel albumin, entrectinib, vandetanib, Bosutinib, vedolizumab, upadacitinib hemihydrate,...
With >9,600 patient-years of exposure, long-term data show low rates of serious AEs with upadacitinib in adolescent & adult #AtopicDermatitis patients, consistent with background incidence rates.
www.hcplive.com/view...
www.hcplive.com/view...
February 4, 2026 at 2:00 AM
With >9,600 patient-years of exposure, long-term data show low rates of serious AEs with upadacitinib in adolescent & adult #AtopicDermatitis patients, consistent with background incidence rates.
www.hcplive.com/view...
www.hcplive.com/view...
Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.
ClinicalTrials.gov
clinicaltrials.gov
January 28, 2026 at 3:25 PM
Upadacitinib in Giant Cell Arteritis (GCA) With Active Large-vessel Involvement.
Upadacitinib (Rinvoq) showed durable clinical benefit at 1 year among children and adolescents with #IBD, a single-center study found. @alanmoss.bsky.social
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Upadacitinib Shows 1-Year Benefit in Pediatric IBD
Single-center study finds durable, steroid-free remission, especially in ulcerative colitis
www.medpagetoday.com
January 26, 2026 at 3:32 PM
Upadacitinib (Rinvoq) showed durable clinical benefit at 1 year among children and adolescents with #IBD, a single-center study found. @alanmoss.bsky.social
www.medpagetoday.com/meetingcover...
www.medpagetoday.com/meetingcover...
Are JAK Inhibitors Better at Pain Relief in RA?
Among RA patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial data.
buff.ly/X86Xd1L
Among RA patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial data.
buff.ly/X86Xd1L
January 23, 2026 at 10:01 PM
Are JAK Inhibitors Better at Pain Relief in RA?
Among RA patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial data.
buff.ly/X86Xd1L
Among RA patients who responded to upadacitinib (Rinvoq) or adalimumab, those receiving upadacitinib had significantly less residual pain with treatment, according to a post hoc analysis of phase III trial data.
buff.ly/X86Xd1L
Efficacy and safety of Rinvoq (upadacitinib) in palmoplantar pustulosis study highlights the complex immune response patterns.
#Psoriasis
psoriasisclub.org/thread-8408....
#Psoriasis
psoriasisclub.org/thread-8408....
Rinvoq and palmoplantar pustular psoriasis
psoriasisclub.org
January 19, 2026 at 11:59 AM
Efficacy and safety of Rinvoq (upadacitinib) in palmoplantar pustulosis study highlights the complex immune response patterns.
#Psoriasis
psoriasisclub.org/thread-8408....
#Psoriasis
psoriasisclub.org/thread-8408....
FWIW, the #s in pediatric trials with Bayesian informative prior can be tiny. e.g. Upadacitinib for UC in adults - phase 2b and phase 3 pubmed.ncbi.nlm.nih.gov/35644166/inc... 1447 adults.
With the prior (Upa works well in UC) you can run a rapid pediatric trial with <= 20 patients to get approval.
With the prior (Upa works well in UC) you can run a rapid pediatric trial with <= 20 patients to get approval.
January 13, 2026 at 5:28 PM
FWIW, the #s in pediatric trials with Bayesian informative prior can be tiny. e.g. Upadacitinib for UC in adults - phase 2b and phase 3 pubmed.ncbi.nlm.nih.gov/35644166/inc... 1447 adults.
With the prior (Upa works well in UC) you can run a rapid pediatric trial with <= 20 patients to get approval.
With the prior (Upa works well in UC) you can run a rapid pediatric trial with <= 20 patients to get approval.
Upadacitinib in resistant Takayasu's arteritis with coexisting ulcerative colitis
Upadacitinib in resistant Takayasu's arteritis with coexisting ulcerative colitis - PubMed
Upadacitinib in resistant Takayasu's arteritis with coexisting ulcerative colitis
pubmed.ncbi.nlm.nih.gov
January 13, 2026 at 3:52 PM
Upadacitinib in resistant Takayasu's arteritis with coexisting ulcerative colitis
one promising off-the-shelf medication
for major type of long-covid so likely also me-cfs
JAK-STAT inhibitors
Baricitinib = Olumiant, Barigen
Upadacitinib = Rinvoq
Tofacitinib = Xeljanz, Jaknat
problem in US they are very expensive as not sold as generics yet
but elsewhere in the world (Canada)
for major type of long-covid so likely also me-cfs
JAK-STAT inhibitors
Baricitinib = Olumiant, Barigen
Upadacitinib = Rinvoq
Tofacitinib = Xeljanz, Jaknat
problem in US they are very expensive as not sold as generics yet
but elsewhere in the world (Canada)
January 11, 2026 at 7:49 PM
one promising off-the-shelf medication
for major type of long-covid so likely also me-cfs
JAK-STAT inhibitors
Baricitinib = Olumiant, Barigen
Upadacitinib = Rinvoq
Tofacitinib = Xeljanz, Jaknat
problem in US they are very expensive as not sold as generics yet
but elsewhere in the world (Canada)
for major type of long-covid so likely also me-cfs
JAK-STAT inhibitors
Baricitinib = Olumiant, Barigen
Upadacitinib = Rinvoq
Tofacitinib = Xeljanz, Jaknat
problem in US they are very expensive as not sold as generics yet
but elsewhere in the world (Canada)
Among rheumatoid arthritis patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of phase III trial data.
https://www.medpagetoday.com/rheumatology/arthritis/119344
https://www.medpagetoday.com/rheumatology/arthritis/119344
Not All Drugs Approved for Rheumatoid Arthritis Are Equal for Pain Relief
Trial data suggest a JAK inhibitor beats the leading biologic
www.medpagetoday.com
January 9, 2026 at 3:05 PM
Among rheumatoid arthritis patients responding to upadacitinib (Rinvoq) or adalimumab, those receiving the former had significantly less residual pain with treatment, according to a post-hoc analysis of phase III trial data.
https://www.medpagetoday.com/rheumatology/arthritis/119344
https://www.medpagetoday.com/rheumatology/arthritis/119344
New findings suggest upadacitinib has the strongest short-term efficacy among oral JAK inhibitors for moderate-to-severe atopic dermatitis. Upadacitinib 30 mg ranked highest across EASI-75, IGA 0/1, and itch outcomes.
🔗View:
🔗View:
Upadacitinib Superior to 4 Other JAKi Monotherapies for Atopic Dermatitis | HCPLive
Investigators ranked the short-term effectiveness of 4 oral JAKis, upadacitinib, abrocitinib, baricitinib, and ivarmacitinib in moderate-to-severe atopic dermatitis.
www.hcplive.com
January 8, 2026 at 4:00 AM
New findings suggest upadacitinib has the strongest short-term efficacy among oral JAK inhibitors for moderate-to-severe atopic dermatitis. Upadacitinib 30 mg ranked highest across EASI-75, IGA 0/1, and itch outcomes.
🔗View:
🔗View:
discovered Canadian Pharmacies are doing something
@costplusdrugs.com either can't or won't
JAK-STAT inhibitors $1/day instead of $25/day
maybe most promising treatment for millions with #LongCovid
@mcuban.bsky.social needs to figure out who in FDA
he needs to give a CAVA bag to make this happen
@costplusdrugs.com either can't or won't
JAK-STAT inhibitors $1/day instead of $25/day
maybe most promising treatment for millions with #LongCovid
@mcuban.bsky.social needs to figure out who in FDA
he needs to give a CAVA bag to make this happen
January 7, 2026 at 3:27 PM
discovered Canadian Pharmacies are doing something
@costplusdrugs.com either can't or won't
JAK-STAT inhibitors $1/day instead of $25/day
maybe most promising treatment for millions with #LongCovid
@mcuban.bsky.social needs to figure out who in FDA
he needs to give a CAVA bag to make this happen
@costplusdrugs.com either can't or won't
JAK-STAT inhibitors $1/day instead of $25/day
maybe most promising treatment for millions with #LongCovid
@mcuban.bsky.social needs to figure out who in FDA
he needs to give a CAVA bag to make this happen
one HUGE thing @mcuban.bsky.social via @costplusdrugs.com
could help us suffering years with #LongCovid
import generics of FDA approved JAK-STAT inhibitors
impossible to afford
$$$$ per month in USA
Baricitinib = Olumiant, Barigen
Upadacitinib = Rinvoq
Tofacitinib = Xeljanz
only hopeful treatment
could help us suffering years with #LongCovid
import generics of FDA approved JAK-STAT inhibitors
impossible to afford
$$$$ per month in USA
Baricitinib = Olumiant, Barigen
Upadacitinib = Rinvoq
Tofacitinib = Xeljanz
only hopeful treatment
December 30, 2025 at 2:03 PM
one HUGE thing @mcuban.bsky.social via @costplusdrugs.com
could help us suffering years with #LongCovid
import generics of FDA approved JAK-STAT inhibitors
impossible to afford
$$$$ per month in USA
Baricitinib = Olumiant, Barigen
Upadacitinib = Rinvoq
Tofacitinib = Xeljanz
only hopeful treatment
could help us suffering years with #LongCovid
import generics of FDA approved JAK-STAT inhibitors
impossible to afford
$$$$ per month in USA
Baricitinib = Olumiant, Barigen
Upadacitinib = Rinvoq
Tofacitinib = Xeljanz
only hopeful treatment
#JAK inhibitors are an important new tool in the arsenal of treatments for #IBD.
Examine the evidence on the use of upadacitinib, tofacitinib, and filgotinib, and what's known about their comparative effectiveness.
👉 buff.ly/6K1ipvK
#UlcerativeColitis #CrohnsDisease
Examine the evidence on the use of upadacitinib, tofacitinib, and filgotinib, and what's known about their comparative effectiveness.
👉 buff.ly/6K1ipvK
#UlcerativeColitis #CrohnsDisease
December 30, 2025 at 2:02 PM
#JAK inhibitors are an important new tool in the arsenal of treatments for #IBD.
Examine the evidence on the use of upadacitinib, tofacitinib, and filgotinib, and what's known about their comparative effectiveness.
👉 buff.ly/6K1ipvK
#UlcerativeColitis #CrohnsDisease
Examine the evidence on the use of upadacitinib, tofacitinib, and filgotinib, and what's known about their comparative effectiveness.
👉 buff.ly/6K1ipvK
#UlcerativeColitis #CrohnsDisease
Case Report: Takayasu Arteritis During Upadacitinib Therapy for Ulcerative Colitis Successfully Treated by Combination Therapy With Methotrexate
Case Report: Takayasu Arteritis During Upadacitinib Therapy for Ulcerative Colitis Successfully Treated by Combination Therapy With Methotrexate - PubMed
Case Report: Takayasu Arteritis During Upadacitinib Therapy for Ulcerative Colitis Successfully Treated by Combination Therapy With Methotrexate
pubmed.ncbi.nlm.nih.gov
December 22, 2025 at 12:00 AM
Case Report: Takayasu Arteritis During Upadacitinib Therapy for Ulcerative Colitis Successfully Treated by Combination Therapy With Methotrexate
Morning FYI:
If you do take some Rinvoq™ (upadacitinib), you can't donate blood or blood components for ONE MONTH after your last dose.
Source: www.carterbloodcare.org/education-ce...
If you do take some Rinvoq™ (upadacitinib), you can't donate blood or blood components for ONE MONTH after your last dose.
Source: www.carterbloodcare.org/education-ce...
December 18, 2025 at 2:14 PM
Morning FYI:
If you do take some Rinvoq™ (upadacitinib), you can't donate blood or blood components for ONE MONTH after your last dose.
Source: www.carterbloodcare.org/education-ce...
If you do take some Rinvoq™ (upadacitinib), you can't donate blood or blood components for ONE MONTH after your last dose.
Source: www.carterbloodcare.org/education-ce...
📸 Gastro Curbside Consult presents an often-forgotten complication of upadacitinib. Click the link to read about the case and try to solve the diagnosis:
🔗 ow.ly/HQbA50XJCZr
🔗 ow.ly/HQbA50XJCZr
December 15, 2025 at 5:54 PM
📸 Gastro Curbside Consult presents an often-forgotten complication of upadacitinib. Click the link to read about the case and try to solve the diagnosis:
🔗 ow.ly/HQbA50XJCZr
🔗 ow.ly/HQbA50XJCZr
AbbVie Seeks Additional Approval for Upadacitinib to Treat Severe Alopecia Areata in Japan#Japan#Tokyo#AbbVie#Alopecia_Areata#Upadacitinib
AbbVie Seeks Additional Approval for Upadacitinib to Treat Severe Alopecia Areata in Japan
AbbVie has applied for additional approval in Japan for upadacitinib, targeting severe alopecia areata cases. This is a critical development for treatment options.
third-news.com
December 15, 2025 at 5:13 AM
AbbVie Seeks Additional Approval for Upadacitinib to Treat Severe Alopecia Areata in Japan#Japan#Tokyo#AbbVie#Alopecia_Areata#Upadacitinib
(Biomed Chrom) Highly Sensitive and Selective Liquid Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study: ABSTRACT
A highly sensitive and… #massSpecRSS #biomedchrom
A highly sensitive and… #massSpecRSS #biomedchrom
Highly Sensitive and Selective Liquid Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study
ABSTRACT
A highly sensitive and versatile liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed for the simultaneous quantification of upadacitinib and atorvastatin in rat plasma. The analytes and internal standard were extracted from 30 μL rat plasma using a simple protein precipitation technique. The method demonstrated excellent linearity over the concentration ranges of 0.5–500 ng/mL for upadacitinib and 0.05–100 ng/mL for atorvastatin and precision over all quality control levels. Detection was achieved using multiple reaction monitoring (MRM) in positive ionization mode. Method validation was carried out in accordance with the current ICH M10 guidance on bioanalytical method validation. The validated method was successfully applied to a pharmacokinetic study of a 10 mg oral formulation of upadacitinib and atorvastatin in rats. The pharmacokinetic results confirmed the applicability of the method for the reliable and simultaneous determination of both analytes in rat plasma.
dlvr.it
December 12, 2025 at 8:05 PM
(Biomed Chrom) Highly Sensitive and Selective Liquid Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study: ABSTRACT
A highly sensitive and… #massSpecRSS #biomedchrom
A highly sensitive and… #massSpecRSS #biomedchrom
Highly Sensitive and Selective Liquid Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study #BiomedChrom analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/...
Highly Sensitive and Selective Liquid Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study
A highly sensitive and versatile liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was developed for the simultaneous quantification of upadacitinib and atorvastatin in rat plasma. The...
analyticalsciencejournals.onlinelibrary.wiley.com
December 12, 2025 at 11:38 AM
Highly Sensitive and Selective Liquid Chromatography–Tandem Mass Spectrometry Method for the Simultaneous Determination of Upadacitinib and Atorvastatin in Rat Plasma and Its Application to a Pharmacokinetic Study #BiomedChrom analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/...
Nou article a #Docusalut: 💊 Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice http://hdl.handle.net/20.500.13003/26056 #PUblicaSalutiB
December 5, 2025 at 3:30 PM
Nou article a #Docusalut: 💊 Treatment with Upadacitinib in Difficult-to-Treat (D2T) Psoriatic Arthritis (PsA): A National Multicenter Study of the First 134 Patients in Clinical Practice http://hdl.handle.net/20.500.13003/26056 #PUblicaSalutiB
ICYMI: Recent real-world data from the SCALE-UP study show adults with #AtopicDermatitis saw rapid improvements with upadacitinib.
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗
SCALE-UP: Findings on Real-World Use of Upadacitinib in Atopic Dermatitis | HCPLive
The SCALE-UP study, assessing patients with atopic dermatitis treated with upadacitinib, points to rapid real‐world efficacy findings on this medication.
hcplive.com
November 28, 2025 at 4:00 PM
ICYMI: Recent real-world data from the SCALE-UP study show adults with #AtopicDermatitis saw rapid improvements with upadacitinib.
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗
✔️ ~66% saw itch relief
✔️ Strong skin clearance
✔️ Better sleep & QoL
🔗
AbbVie Reports Positive Phase 3 Results for Upadacitinib in Treating Non-Segmental Vitiligo#United_States#AbbVie#North_Chicago#Upadacitinib#Non-Segmental_Vitiligo
AbbVie Reports Positive Phase 3 Results for Upadacitinib in Treating Non-Segmental Vitiligo
AbbVie has announced successful Phase 3 trial results for Upadacitinib in treating Non-Segmental Vitiligo in adults and adolescents, marking a significant milestone.
third-news.com
November 27, 2025 at 5:58 AM
AbbVie Reports Positive Phase 3 Results for Upadacitinib in Treating Non-Segmental Vitiligo#United_States#AbbVie#North_Chicago#Upadacitinib#Non-Segmental_Vitiligo